Marplan (isocarboxazid) NDC 72336-032

NDC codes

FDA NDC Directory

Product NDC (as listed)72336-032Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72336-0032Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72336-032-01	72336003201	100 TABLET in 1 BOTTLE, PLASTIC (72336-032-01)Marketed from Jul 1, 1959

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Marplan
Generic name (nonproprietary): isocarboxazid
Active ingredients: Isocarboxazid — 10 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Lifsa Drugs LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 011961
Marketing start: Jul 1, 1959
Listing expires: Dec 31, 2027
Other FDA classes: Monoamine Oxidase Inhibitors (Mechanism)
Identifiers: Product ID 72336-032_97745d9b-c2a6-45e3-9e1e-7fabec4681fbSPL ID 97745d9b-c2a6-45e3-9e1e-7fabec4681fbSPL set ID 95fde749-44ad-4668-86c4-0ff17bca0074RxCUI 104837, 201708UNII 34237V843TUPC 0372336032018
Pharmacologic class: Monoamine Oxidase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472336003201 followed by a unit qualifier and the quantity

Package 72336-0032-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 21, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Marplan is indicated for the treatment of depression. Because of its potentially serious side effects, Marplan is not an antidepressant of first choice in the treatment of newly diagnosed depressed patients. The efficacy of Marplan in the treatment of depression was established in 6-week controlled trials of depressed outpatients. These patients had symptoms that corresponded to the DSM-IV category of major depressive disorder; however, they often also had signs and symptoms of anxiety (anxious mood, panic, and/or phobic symptoms) ( see CLINICAL PHARMACOLOGY ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at lea…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)